Back to top
more

Corcept Therapeutics (CORT)

(Delayed Data from NSDQ)

$33.88 USD

33.88
1,047,351

+0.59 (1.77%)

Updated Jul 19, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Timber (TMBR) to Get Acquired by LEO Pharma for $36M, Stock Up

by Zacks Equity Research

Timber (TMBR) surges as LEO Pharma offers to acquire it for approximately $36 million.

Anebulo (ANEB) Gains on Positive FDA Response for ANEB-001

by Zacks Equity Research

Anebulo (ANEB) gains on positive FDA response for the phase III development of its lead candidate ANEB-001 for treating patients with acute cannabinoid intoxication.

Calliditas (CALT) Up as sNDA for Tarpeyo Gets Priority Review

by Zacks Equity Research

Calliditas (CALT) soars as the supplement new drug application seeking to convert accelerated approval of Tarpeyo delayed-release capsule to full approval gets accepted by the FDA.

Belite Bio (BLTE) Stock Surges 72% in a Month: Here's Why

by Zacks Equity Research

Belite Bio (BLTE) rises 72% in a month due to encouraging progress on the development of the company's lead product candidate Tinlarebant, which is being developed to treat several eye diseases.

Amphastar Pharma (AMPH) Stock Skyrockets 89% YTD: Here's Why

by Zacks Equity Research

Amphastar Pharma (AMPH) shares are up 89.1% year to date due to the acquisition of Baqsimi from Lilly. The company also receives FDA approval for Naloxone.

Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio

by Zacks Equity Research

Dr. Reddy's (RDY) continues to enjoy a strong foothold in the global generics market due to its deep generic drugs pipeline. The company is also looking to strengthen its biosimilars portfolio.

Pieris (PIRS) Up On Receiving Milestone Payment From Partner

by Zacks Equity Research

Pieris (PIRS) soars as partner Boston Pharmaceuticals initiated early-stage study of PRS-342/BOS-342, triggering an undisclosed milestone payment to the former.

bluebird's (BLUE) Lovo-cel to Not Face Advisory Committee

by Zacks Equity Research

bluebird (BLUE) announces that its gene therapy, lovotibeglogene autotemcel, developed for sickle cell disease, will not be scheduled for advisory committee meeting, thereby accelerating the path for approval.

Sonnet (SONN) Up as Ovarian Cancer Drug Enters Clinical Study

by Zacks Equity Research

Sonnet (SONN) receives FDA clearance to begin clinical development for its combination therapy of SON-1010 and Roche's atezolizumab, for the potential treatment of platinum-resistant ovarian cancer.

Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus

by Zacks Equity Research

Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after discontinuing the tarcocimab program.

Galecto (GLTO) Down 71% as Lung Disease Candidate Fails

by Zacks Equity Research

Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fails to meet its primary endpoint.

Nektar (NKTR) Stock Surges 75% in a Week: Here's Why

by Zacks Equity Research

Nektar's (NKTR) shares rally almost 75% in a week on corrected efficacy data for rezpeg studies, earlier miscalculated by Eli Lilly.

Immunovant (IMVT) Q1 Loss Wider Y/Y, Pipeline in Focus

by Zacks Equity Research

Immunovant's (IMVT) reports wider-than-expected loss for fiscal first-quarter 2023. IMVT is on track with the pipeline developments.

Will Corcept (CORT) Gain on Rising Earnings Estimates?

by Zacks Equity Research

Corcept (CORT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Jazz (JAZZ) Beats on Q2 Earnings & Sales, Raises '23 View

by Zacks Equity Research

Jazz (JAZZ) reports better-than-expected second-quarter results as earnings and sales beat expectations. The company raises its financial guidance for 2023.

Corcept (CORT) Beats on Q2 Earnings, Ups '23 Sales View

by Zacks Equity Research

Corcept's (CORT) second-quarter earnings and revenues beat estimates. The company gives updates on its pipelines and raises revenue guidance for 2023, reflecting strong performance of Korlym.

Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Corcept (CORT) delivered earnings and revenue surprises of 66.67% and 7.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ImmunoGen (IMGN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ImmunoGen (IMGN) delivered earnings and revenue surprises of 87.50% and 94.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Corcept Therapeutics (CORT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Corcept's (CORT) Early-Stage Study on NASH Reveals Positive Data

by Zacks Equity Research

Corcept's (CORT) early-stage candidate miricorilant, evaluated to treat patients with presumed non-alcoholic steatohepatitis, shows encouraging data.

Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept (CORT) Down 4.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance

by Zacks Equity Research

Corcept (CORT) first-quarter earnings miss estimates, while revenues beat the same. The company gives updates on its pipelines and raises revenue guidance for 2023.

Corcept Therapeutics (CORT) Lags Q1 Earnings Estimates

by Zacks Equity Research

Corcept (CORT) delivered earnings and revenue surprises of -30% and 1.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Ekta Bagri headshot

Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More

by Ekta Bagri

Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.